Clinical trials: PD-1 Inhibitors
Elderly Patients (>65 Years), Non-Small Cell Lung Cancer
Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
The goal of this clinical trial is to elucidate the clinical efficacy and safety of electroacupuncture combined with PD-1 inhibitor therapy in elderly patients with advanced non-small cell lung cancer (NSCLC) through a…
- Conditions
- Elderly Patients (>65 Years), Non-Small Cell Lung Cancer, PD-1 Inhibitors, Electroacupuncture
- Trial name
- NCT07086300
- Testing
- Electroacupuncture (EA)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Kong Fanming
Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy, Gastrointestinal Tumors
Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment
Evaluating the efficacy and safety of Neoantigen Personalized Cancer Vaccine deepGeneAI-001 in combination with Sintilimab in the treatment of Gastrointestinal Solid Tumors
- Trial name
- PCV-GSTT (NCT07067385)
- Testing
- Neoantigen Personalized Cancer Vaccine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Nasopharyngeal Neoplasms, PD-1 Inhibitor
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined…
- Conditions
- Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
- Trial name
- NCT06811844
- Testing
- Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy
- Where
- 3 sites in China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Gastric (Stomach) Cancer, Gastric Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic…
- Conditions
- Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
- Trial name
- NCT06871527
- Testing
- fruquintinib + tislelizumab + FOLFOX
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Hepatocellular Carcinoma, Lenvatinib
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy
- Trial name
- NCT06333561
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Radiotherapy
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
PD-1 inhibitor plus anti-VEGFR has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors
- Trial name
- NCT06708650
- Testing
- Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guiping People's Hospital
Metastatic Melanoma, Immune Checkpoints Inhibitors
Biomarkers in Immunotherapy of Melanoma
Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs).
- Conditions
- Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral), Exosomal mRNA Expression of PD-L1 and IFNγ
- Trial name
- NCT05878977
- Testing
- Immune checkpoint inhibitor
- Where
- Slovenia
- Volunteers
- 150 people
- Sponsor
- Institute of Oncology Ljubljana
Stereotactic Body Radiotherapy, PD-1 Inhibitors
Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer
The goal of this observational study is to investigate the efficacy and safety of stereotactic body radiotherapy combined with PD-1 blockers for LAPC and LRPC.
- Conditions
- Stereotactic Body Radiotherapy, PD-1 Inhibitors, Pancreatic Cancer
- Trial name
- NCT06195254
- Testing
- Stereotactic body radiotherapy (SBRT), PD-1 blocking antibody
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Peking University Third Hospital
Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors
IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)
This is a single-center, prospective, single-arm Phase II clinical study to evaluate the efficacy and safety of IBI110 in combination with Sintilimab in subjects with advanced or metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT06078657
- Testing
- IBI110+Sintilimab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Nasopharyngeal Carcinoma, PD-1 Inhibitors
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial
programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still…
- Conditions
- Nasopharyngeal Carcinoma, PD-1 Inhibitors, Chemoradiotherapy
- Trial name
- NCT05520814
- Testing
- PD-1 inhibitors, chemoradiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Neoadjuvent, PD-1 Inhibitor
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
The aim of this study was to investigate the efficacy and safety of pembrolizumab combined with albumin paclitaxel and cisplatin versus albumin paclitaxel and cisplatin or 5-fluorouracil and cisplatin in neoadjuvant therapy for…
- Conditions
- Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06006650
- Testing
- Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 114 people
- Sponsor
- Tang-Du Hospital
Carcinoma, Intrahepatic Cholangiocarcinoma
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients…
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor
- Trial name
- NCT05913661
- Testing
- Pemigatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma, Regorafenib
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
This is a single arm, nonrandomized, single center clinical study to investigate the safety and efficacy of regorafenib combined with PD-1 inhibitor therapy for second-line treatment of hepatocellular carcinoma
- Conditions
- Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor
- Trial name
- NCT05048017
- Testing
- Regorafenib, PD-1 inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated…
- Conditions
- Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor, VEGF
- Trial name
- NCT05675033
- Testing
- Serplulimab and Bevacizumab injection
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Carotid Artery Plaque, Pd-1 Inhibitors
Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients
This is a single-center, prospective cohort study on the comparison of clinical outcomes of carotid plaques in PD-1-treated tumor patients vs non-PD-1-treated tumor patients.
- Trial name
- NCT05549336
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC
SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC
The aim of this trial is to investigate the primary efficacy of SBRT combined with PD-1 inhibitor and thoracic hyperthermia in patients with EGFR, ALK, and ROS1 negative stage IV NSCLC patients who progressed after first-line…
- Trial name
- NCT05520853
- Testing
- SBRT combined with PD-1 inhibitors and thoracic hyperthermia
- Where
- China
- Volunteers
- 63 people
- Sponsor
- First People's Hospital of Hangzhou
Urothelial Carcinoma Bladder, PD-1 Inhibitor
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
This is a phase II open label single-arm prospective study aiming to investigate the efficacy of PD-1 inhibitor Tislelizumab combined with conventional gemcitabine and cisplatin as bladder sparing treatment for patients with…
- Trial name
- NCT05401279
- Testing
- Tislelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma
PD-1 Inhibitors With or Without Radiation in Advanced Melanoma
This trial was a single-center, prospective, randomized controlled phase II trial. The objective was to evaluate the efficacy and safety of PD-1 inhibitors with or without radiotherapy in patients with advanced melanoma.
- Trial name
- NCT05498805
- Testing
- Radiation
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma, PD-1 Inhibitor
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
200 patients with advanced esophageal cancer who received PD-1 monoclonal antibody treatment would be enrolled in this study. Changes in peripheral blood immune cells before and after treatment would be recorded and used for…
- Trial name
- NCT05392413
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
This is a updated trial of NCT04188860 as a multi-center study. For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors
- Trial name
- NCT05290935
- Testing
- Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Lei Li